HC Wainwright restated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a $40.00 target price on the biotechnology company’s stock.
Capricor Therapeutics Price Performance
CAPR stock opened at $4.99 on Tuesday. The stock has a market cap of $159.58 million, a price-to-earnings ratio of -5.74 and a beta of 3.92. The company has a 50 day simple moving average of $4.36 and a 200 day simple moving average of $5.18. Capricor Therapeutics has a 1 year low of $2.68 and a 1 year high of $7.28.
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. The business had revenue of $3.97 million during the quarter, compared to the consensus estimate of $4.51 million. On average, equities research analysts anticipate that Capricor Therapeutics will post -1.24 EPS for the current fiscal year.
Institutional Inflows and Outflows
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Read More
- Five stocks we like better than Capricor Therapeutics
- Conference Calls and Individual Investors
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- The Role Economic Reports Play in a Successful Investment Strategy
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Airline Stocks – Top Airline Stocks to Buy Now
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.